Clinical Trial · NCT07848243

Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

Overview

\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors

Sponsor

Peking University Cancer Hospital & Institute

Phase

Phase 2

Contacts

Hua Zhu (PRINCIPAL_INVESTIGATOR)

Hua Zhu (CONTACT)

zhuhuabch@pku.edu.cn

010-88196495

ClinicalTrials.gov

NCT07848243

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

PDL1-3

Isotope(s):

Target(s):

PD-L1

Ligand Class: Small Molecules

Eligibility

Inclusion

subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors;
There was at least one measurable target lesion according to RECIST1.1 criteria;
Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements;

Exclusion

Severe abnormal liver and kidney function.
Unable to lie flat for half an hour.
Claustrophobia or other mental illness.